LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC
JS Lee, Shunichi Sugawara, Jin Hyoung Kang, Hye Ryun Kim, Naoki Inui, Toyoaki Hida, K.H. Lee, Tsutomu Yoshida, Hiroshi Tanaka, Cheng‐Ta Yang, Makoto Nishio, Yuichiro Ohe, Tomohide Tamura, Nobuyuki Yamamoto, Chong‐Jen Yu, Hiroaki Akamatsu, Yoshinobu Namba, Naoki Sumiyoshi, Kazuhiko Nakagawa
Topics & Concepts
MedicineNivolumabBevacizumabInternal medicineCarboplatinOncologyClinical endpointInterim analysisHazard ratioPlaceboProgression-free survivalChemotherapyRandomized controlled trialCancerConfidence intervalImmunotherapyPathologyCisplatinAlternative medicineCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentEsophageal Cancer Research and Treatment